CL2015002627A1 - Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol - Google Patents
Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamolInfo
- Publication number
- CL2015002627A1 CL2015002627A1 CL2015002627A CL2015002627A CL2015002627A1 CL 2015002627 A1 CL2015002627 A1 CL 2015002627A1 CL 2015002627 A CL2015002627 A CL 2015002627A CL 2015002627 A CL2015002627 A CL 2015002627A CL 2015002627 A1 CL2015002627 A1 CL 2015002627A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- compositions
- dipiridamol
- preferibly
- eye disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
LA PRESENTE INVENCIÓN DESCRIBE COMPOSICIONES PARA EL USO EN EL TRATAMIENTO DE TRASTORNOS OCULARES, LAS COMPOSICIONES QUE INCLUYEN UNA CANTIDAD EFECTIVA DE UN DIPIRIDAMOL ADMINISTRADO TÓPICAMENTE. PREFERIBLEMENTE, EL DIPIRIDAMOL ADMINISTRADO TÓPICAMENTE ES FORMULADO COMO UNA SOIUCION. PREFERIBLEMENTE, EL DIPIRIDAMOL ADMINISTRADO TÓPICAMENTE ES AL MENOS UN AGENTE SELECCIONADO DEL GRUPO QUE CONSISTENTE DE: DIPIRIDAMOL, Y SU SAL FARMACÉUTICAMENTE ACEPTABLE. PREFERIBLEMENTE, LA CANTIDAD EFECTIVA CORRESPONDE A UNA CONCENTRACIÓN DE POR LO MENOS APROXIMADARNENTE UNA MOLARIDAD DE 10-5. PREFERIBLEMENTE, LA CANTIDAD EFECTIVA SE BASA EN LA ADMINISTRACIÓN DE UN TRATAMIENTO DE AL MENOS UNA VEZ CADA DOS DIAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL225179A IL225179A (en) | 2013-03-12 | 2013-03-12 | Compounds for use in ocular disorders using dipyridamole |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015002627A1 true CL2015002627A1 (es) | 2016-03-11 |
Family
ID=48916407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015002627A CL2015002627A1 (es) | 2013-03-12 | 2015-09-11 | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2968328A4 (es) |
JP (1) | JP6820658B2 (es) |
KR (2) | KR20210010638A (es) |
CN (1) | CN105188702B (es) |
AU (1) | AU2014229371B2 (es) |
BR (1) | BR112015022084A2 (es) |
CA (1) | CA2905594A1 (es) |
CL (1) | CL2015002627A1 (es) |
EA (1) | EA035966B1 (es) |
IL (1) | IL225179A (es) |
MX (1) | MX2015012716A (es) |
MY (1) | MY182591A (es) |
SG (2) | SG11201507092QA (es) |
WO (1) | WO2014141079A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI725008B (zh) * | 2015-01-28 | 2021-04-21 | 瑞采生技有限公司 | 用於增強PPARγ表現及核轉位之化合物及其醫療用途 |
US20180092776A1 (en) | 2016-09-30 | 2018-04-05 | Sara Heikali | Method and device for treating and managing diseased ocular tissue |
WO2021001806A1 (en) | 2019-07-04 | 2021-01-07 | Ocular Discovery Ltd. | Stable dipyridamole formulations with reduced impurities |
WO2021001805A1 (en) | 2019-07-04 | 2021-01-07 | Ocular Discovery Ltd. | Stable dipyridamole formulations and their methods of preparation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07258084A (ja) * | 1994-03-17 | 1995-10-09 | Rohto Pharmaceut Co Ltd | ジピリダモールを必須成分とする眼圧降下剤 |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
CA2628570A1 (en) * | 2005-11-09 | 2007-05-18 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
WO2010056710A1 (en) * | 2008-11-11 | 2010-05-20 | Biovista, Inc. | Compositions and methods for treating eye diseases |
EP2363126A1 (en) * | 2010-03-04 | 2011-09-07 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation |
-
2013
- 2013-03-12 IL IL225179A patent/IL225179A/en active IP Right Grant
-
2014
- 2014-03-11 BR BR112015022084A patent/BR112015022084A2/pt active Search and Examination
- 2014-03-11 EP EP14764673.1A patent/EP2968328A4/en not_active Withdrawn
- 2014-03-11 MX MX2015012716A patent/MX2015012716A/es unknown
- 2014-03-11 JP JP2015562486A patent/JP6820658B2/ja active Active
- 2014-03-11 CN CN201480016302.6A patent/CN105188702B/zh not_active Expired - Fee Related
- 2014-03-11 AU AU2014229371A patent/AU2014229371B2/en not_active Ceased
- 2014-03-11 KR KR1020217001495A patent/KR20210010638A/ko not_active Application Discontinuation
- 2014-03-11 CA CA2905594A patent/CA2905594A1/en not_active Abandoned
- 2014-03-11 EA EA201591653A patent/EA035966B1/ru unknown
- 2014-03-11 WO PCT/IB2014/059645 patent/WO2014141079A1/en active Application Filing
- 2014-03-11 SG SG11201507092QA patent/SG11201507092QA/en unknown
- 2014-03-11 MY MYPI2015002196A patent/MY182591A/en unknown
- 2014-03-11 KR KR1020157027571A patent/KR20150126021A/ko not_active IP Right Cessation
- 2014-03-11 SG SG10201706937UA patent/SG10201706937UA/en unknown
-
2015
- 2015-09-11 CL CL2015002627A patent/CL2015002627A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2014229371A1 (en) | 2015-10-29 |
WO2014141079A1 (en) | 2014-09-18 |
KR20210010638A (ko) | 2021-01-27 |
MX2015012716A (es) | 2016-07-06 |
SG11201507092QA (en) | 2015-10-29 |
EP2968328A4 (en) | 2016-11-23 |
EP2968328A1 (en) | 2016-01-20 |
MY182591A (en) | 2021-01-26 |
EA035966B1 (ru) | 2020-09-07 |
IL225179A (en) | 2017-01-31 |
SG10201706937UA (en) | 2017-09-28 |
CN105188702A (zh) | 2015-12-23 |
IL225179A0 (en) | 2013-06-27 |
CA2905594A1 (en) | 2014-09-18 |
JP6820658B2 (ja) | 2021-01-27 |
KR20150126021A (ko) | 2015-11-10 |
EA201591653A1 (ru) | 2017-05-31 |
BR112015022084A2 (pt) | 2017-07-18 |
AU2014229371B2 (en) | 2018-05-10 |
JP2016514123A (ja) | 2016-05-19 |
CN105188702B (zh) | 2019-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BR112018015273A2 (pt) | derivados de benzimidazol como moduladores de ror-gama | |
BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
EA201690044A1 (ru) | Модуляторы ядерного транспорта и их применение | |
CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
CO2018009563A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
BR112016007946A2 (pt) | combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
BR112016026545A8 (pt) | eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama | |
CL2015002627A1 (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol | |
EA201690323A1 (ru) | Способы лечения заболеваний уха у детей | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
DOP2016000003A (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán | |
CL2019003463A1 (es) | Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas. | |
PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis | |
BR112014015578A2 (pt) | composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide |